{"id":"https://openalex.org/W4308382005","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.1366","title":"1366 Anti-PD-1/IL-7v bispecific antibody promotes TCF1+ stem like T cells expansion and long-lasting in vivo efficacy","display_name":"1366 Anti-PD-1/IL-7v bispecific antibody promotes TCF1+ stem like T cells expansion and long-lasting in vivo efficacy","publication_year":2022,"publication_date":"2022-11-01","ids":{"openalex":"https://openalex.org/W4308382005","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.1366"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2022-sitc2022.1366","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.1366","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-sitc2022.1366","pdf_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A1417.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A1417.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023411196","display_name":"Aurore Morello","orcid":"https://orcid.org/0000-0003-3202-3779","observed_orcids":["https://orcid.org/0000-0003-3202-3779"]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Aurore Morello","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, France","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052078960","display_name":"Margaux Seit\u00e9","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Margaux Seite","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, France","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029438699","display_name":"Justine Durand","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Justine Durand","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, France","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000095429","display_name":"Isabelle Girault","orcid":"https://orcid.org/0000-0002-9587-5197","observed_orcids":["https://orcid.org/0000-0002-9587-5197"]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Isabelle Girault","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, France","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087659024","display_name":"G\u00e9raldine Teppaz","orcid":"https://orcid.org/0000-0002-5835-2493","observed_orcids":["https://orcid.org/0000-0002-5835-2493"]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Geraldine Teppaz","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, France","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032120204","display_name":"Virginie Th\u00e9penier","orcid":"https://orcid.org/0000-0003-3675-9281","observed_orcids":["https://orcid.org/0000-0003-3675-9281"]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Virginie Thepenier","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, France","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012547336","display_name":"Vanessa Gauttier","orcid":"https://orcid.org/0000-0002-4297-0449","observed_orcids":["https://orcid.org/0000-0002-4297-0449"]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Vanessa Gauttier","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, France","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109591004","display_name":"Caroline Mary","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Caroline Mary","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, France","institution_ids":["https://openalex.org/I4210101439"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5048543389","display_name":"Nicolas Poirier","orcid":"https://orcid.org/0000-0003-2335-9385","observed_orcids":["https://orcid.org/0000-0003-2335-9385"]},"institutions":[{"id":"https://openalex.org/I4210101439","display_name":"OSE Immunotherapeutics (France)","ror":"https://ror.org/00p3g3670","country_code":"FR","type":"company","lineage":["https://openalex.org/I4210101439"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Nicolas Poirier","raw_affiliation_strings":["OSE Immunotherapeutics, Nantes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"OSE Immunotherapeutics, Nantes, France","institution_ids":["https://openalex.org/I4210101439"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210101439"],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9833999872207642,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9833999872207642,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.011300000362098217,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.002300000051036477,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.6169999837875366},{"id":"https://openalex.org/keywords/il-7-receptor-signaling","display_name":"IL-7 receptor signaling","score":0.8690000176429749},{"id":"https://openalex.org/keywords/treg-suppressive-function","display_name":"Treg suppressive function","score":0.6169999837875366},{"id":"https://openalex.org/keywords/t-cell-exhaustion","display_name":"T cell exhaustion","score":0.625},{"id":"https://openalex.org/keywords/immunocytokines","display_name":"immunocytokines","score":0.7419999837875366},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.6930000185966492},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.824999988079071},{"id":"https://openalex.org/keywords/interferon-gamma","display_name":"interferon-gamma","score":0.6190000176429749}],"concepts":[{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.5978327989578247},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5950477123260498},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5734584331512451},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.5363928079605103},{"id":"https://openalex.org/C2777371288","wikidata":"https://www.wikidata.org/wiki/Q410130","display_name":"Interleukin 2","level":3,"score":0.42451101541519165},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.3906208872795105},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3880752921104431},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.36044639348983765},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3377925157546997},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3275260925292969},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3101062774658203},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.30304813385009766},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.28065335750579834},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08162590861320496},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/jitc-2022-sitc2022.1366","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.1366","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-sitc2022.1366","pdf_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A1417.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2022-sitc2022.1366","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.1366","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-sitc2022.1366","pdf_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A1417.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4308382005.pdf","grobid_xml":"https://content.openalex.org/works/W4308382005.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4362593042","https://openalex.org/W4388076782","https://openalex.org/W3213644291","https://openalex.org/W3179045106","https://openalex.org/W3083021188","https://openalex.org/W4282983920","https://openalex.org/W4308402905","https://openalex.org/W3098125533","https://openalex.org/W4308385519","https://openalex.org/W4308399169"],"abstract_inverted_index":{"Background":[0],"Immunocytokines":[1],"can":[2,124],"strengthen":[3,395],"anti-PD-(L)1":[4],"therapy":[5,397],"by":[6,77,264,317],"promoting":[7,318],"T-cell":[8,79,117,325,334,392],"survival,":[9],"but":[10],"their":[11,18],"shortened":[12],"half-life":[13],"and":[14,42,47,54,73,93,134,157,195,204,219,236,259,268,286,313,323,367,386],"systemic":[15],"toxicity":[16],"limit":[17],"clinical":[19],"development.":[20],"We":[21,127],"propose":[22,128],"to":[23,27,36,103,105,132,147,180,189,255,359,362,394],"selectively":[24],"deliver":[25],"IL-7":[26,102,123,183,299,358],"PD-1+":[28,199],"T-cells":[29,109,212,232,241,244,316,321,361],"using":[30],"a":[31,97,119,136,181,193,288],"bispecific":[32],"anti-PD1/IL-7v":[33,275],"mutein":[34,184],"fused":[35,179],"reinvigorate":[37],"PD1+IL-7R+":[38],"tumor-specific":[39,78,108,360],"T":[40],"cells":[41],"sustain":[43,106,363],"long-term":[44,64,206],"response.":[45,110],"RNAseq":[46],"TILs":[48],"scRNAseq":[49,218],"analyses":[50,221,304],"illustrate":[51],"that":[52,223,309],"IL-7R":[53,55,72,74,113,142,190],"pathway":[56,75],"gene":[57],"expression":[58,76,114],"is":[59,81],"significantly":[60,82],"correlated":[61,83],"with":[62,84,129,337],"better":[63],"OS":[65],"and/or":[66],"PFS":[67],"across":[68],"several":[69],"cancers":[70],"Higher":[71],"clonotype":[80,118],"ICI":[85,374],"response,":[86,365],"higher":[87],"stemness":[88],"&":[89,257],"proliferative":[90],"signature,lower":[91],"exhaustion":[92],"apoptosis":[94],"markers,":[95],"providing":[96],"strong":[98],"rationale":[99],"of":[100,122,198,208,228,240,270,315,354,357,369,383,390],"co-targeting":[101],"PD-1":[104,281,289,396],"durable":[107],"Despite":[111],"low":[112],"on":[115],"Tumor-specific":[116],"high":[120],"concentration":[121],"rescue":[125],"them.":[126],"the":[130,149,152,226,261,328,352,381,388],"anti-PD-1/IL-7v":[131],"cis-target":[133],"provide":[135],"survival/proliferative":[137],"specific":[138],"signal.":[139],"Methods":[140],"Proliferation,":[141],"signaling":[143],"assays":[144],"were":[145,161,166],"tested":[146],"determine":[148],"mechanism.":[150],"For":[151],"suppressive":[153],"assay,":[154],"CD4":[155],"Treg":[156,252,262],"autologous":[158],"CD8":[159,271],"Teff":[160,250],"co-cultured.":[162],"In":[163,273],"vivo":[164,346],"experiments":[165],"performed":[167],"in":[168,213,280,287,295,305,340,345],"hPD-1KI":[169],"immunocompetent":[170],"mice.":[171],"Results":[172],"A":[173],"high-affinity":[174],"antagonist":[175],"anti-PD-1":[176,297,332],"mAb":[177],"was":[178],"single":[182],"(IL7v)":[185],"having":[186],"lower":[187],"affinity":[188],"complex":[191],"allowing":[192],"preferential":[194],"optimal":[196],"cis-potentiation":[197],"T-cells.":[200],"Anti-PD1/IL7v":[201],"restores":[202],"proliferation":[203,269,322],"maintains":[205],"survival":[207,368],"chronically":[209],"stimulated":[210,249],"human":[211],"vitro":[214],"(over":[215],"5":[216],"stimulation).":[217],"FACs":[220],"demonstrated":[222],"anti-PD1/IL7v":[224,247,310],"triggers":[225],"expansion":[227,389],"TCF1+":[229],"stem-like":[230,391],"memory":[231],"(CCR7+PD1+KI67+),":[233],"whereas":[234,331],"IL-2":[235,256],"IL-15":[237,258],"promote":[238],"differentiation":[239],"into":[242,327],"exhausted":[243],"(TCF1-Tim3+Ki67+).":[245],"Furthermore,":[246],"preferentially":[248,377],"over":[251],"as":[253],"opposed":[254],"abrogated":[260],"suppression":[263],"restoring":[265],"IFN-\u03b3":[266],"secretion":[267],"Teff.":[272],"vivo,":[274],"has":[276,300],"impressive":[277],"monotherapy":[278],"efficacy":[279],"sensitive":[282],"model":[283,291,307,342],"(orthotopic":[284,292],"mesothelioma,>90%CR)":[285],"resistant":[290],"HCC,>65%":[293],"CR)":[294],"which":[296],"or":[298],"no":[301],"effect.":[302],"Further":[303],"HCC":[306,341],"demonstrate":[308],"enhanced":[311],"quality":[312],"biodistribution":[314],"intratumoral":[319],"TCF1+CD8+stem-like":[320],"favoring":[324],"migration":[326],"tumor":[329],"nest":[330],"promotes":[333],"exclusion.":[335],"Combination":[336],"sorafenib":[338],"chemotherapy":[339],"further":[343],"enhances":[344],"efficacy.":[347,398],"Conclusions":[348],"Our":[349],"data":[350],"validate":[351],"rational":[353],"selective":[355],"delivery":[356],"long-lasting":[364],"proliferation,":[366],"these":[370],"key":[371],"effectors":[372],"upon":[373],"therapy.":[375],"Anti-PD1/IL-7v":[376],"cis-potentiates":[378],"PD1+-tumor-specific-T-cells":[379],"limiting":[380],"risk":[382],"I-O/I-O":[384],"immunotoxicity":[385],"induces":[387],"capable":[393]},"counts_by_year":[{"year":2024,"cited_by_count":1}],"updated_date":"2026-11-13T13:42:25.865203","created_date":"2022-11-11T00:00:00"}